Advertisement

Insulin-Like Growth Factors and Breast Cancer Therapy

  • Xianke Zeng
  • Douglas Yee
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 608)

Abstract

Despite improvements in breast cancer therapy in recent years, additional therapies need to be developed. New therapies may have activity by themselves or may have utility in combination with other agents. Population, preclinical, and basic data suggest the insulin-like growth factor (IGF) system functions to maintain the malignant phenotype in breast cancer. Since the IGFs act via transmembrane tyrosine kinase receptors, targeting of the key receptors could provide a new pathway in breast cancer. In addition, IGF action enhances cell survival, so combination of anti-IGF therapy with conventional cytotoxic drugs could lead to synergistic effects. In this review, we will discuss the rationale for targeting the IGF system, potential methods to disrupt IGF signaling, and identify potential interactions between IGF inhibitors and other anti-tumor strategies. We will also identify important issues to consider when designing clinical trials.

Keywords

Breast Cancer Breast Cancer Cell Breast Cancer Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Tiwari RC, Murray T et al. Cancer statistics 2004, CA Cancer J Clin 2004; 54(1):8–29.PubMedGoogle Scholar
  2. 2.
    Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998; 352(9132)930–942.Google Scholar
  3. 3.
    Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11):783–792.PubMedGoogle Scholar
  4. 4.
    Yee D. The insulin-like growth factors and breast cancer—revisited. Breast Cancer Res Treat 1998; 47(3):197–199.PubMedGoogle Scholar
  5. 5.
    Papa V, Gliozzo B. Clark GM et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993; 53(16):3736–3740.PubMedGoogle Scholar
  6. 6.
    Resnik JL, Reichart DB, Huey K et al. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998; 58(6):1159–1164.PubMedGoogle Scholar
  7. 7.
    Li BD, Khosravi MJ, Berkel HJ et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 2001; 91(5):736–739.PubMedGoogle Scholar
  8. 8.
    Michels KB, Willett WC. Breast cancer—early life matters. N Engl J Med 2004; 351(16):1679–1681.PubMedGoogle Scholar
  9. 9.
    Lu Y, Zi X, Zhao Y et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93(24):1852–1857.PubMedGoogle Scholar
  10. 10.
    Wen B, Deutsch E, Marangoni E et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 2001; 85(12):2017–2021.PubMedGoogle Scholar
  11. 11.
    Pollak MN, Schernhammer ES, Hankinson SE Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4(7):505–518.PubMedGoogle Scholar
  12. 12.
    Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001; 8(3):197–209.PubMedGoogle Scholar
  13. 13.
    Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology 2002; 63(4):317–332.PubMedGoogle Scholar
  14. 14.
    Laban C, Bustin SA, Jenkins PJ. The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 2003; 14(1):28–34.PubMedGoogle Scholar
  15. 15.
    Baker J, Liu JP, Robertson EJ et al. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75(1):73–82.PubMedGoogle Scholar
  16. 16.
    DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Natur 1990; 345(6270):78–80.Google Scholar
  17. 17.
    Ahlgren M, Melbye M, Wohlfahrt J et al. Growth patterns and the risk of breast cancer in women. N Engl J Med 2004; 351(16):1619–1626.PubMedGoogle Scholar
  18. 18.
    Kim HS, Ingermann AR, Tsubaki J et al. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through, a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res 2004; 64(6):2229–2237.PubMedGoogle Scholar
  19. 19.
    Pandini G, Frasca F, Mineo R et al. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277(42):39684–39695.PubMedGoogle Scholar
  20. 20.
    Pandini G, Vigneri R, Costantino A et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999; 5(7):1935–1944.PubMedGoogle Scholar
  21. 21.
    Zhang X, Yee D. Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2000; 2(3):170–175.PubMedGoogle Scholar
  22. 22.
    Ahmad S, Singh N, Glazer RI. Role of AKT1 in 17beta-estradiol-and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharmacol 1999; 58(3):425–430.PubMedGoogle Scholar
  23. 23.
    Hankins GR, Desouza AT, Bentley RC et al. M6P/IGF2 receptor: A candidate breast tumor suppressor gene. Oncogene 1996; 12(9):2003–2009.PubMedGoogle Scholar
  24. 24.
    Marshman E, Green KA, Flint DJ et al. Insulin-like growth factor binding protein 5 and apoptosis in mammary epithelial cells. J Cell Sci 2003; 116(Pt 4):675–682.PubMedGoogle Scholar
  25. 25.
    Deeks S, Richards J, Nandi S. Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor 1. Exp Cell Res 1988; 174(2):448–460.PubMedGoogle Scholar
  26. 26.
    Richert MM, Wood TL. The insulin-like growth factors (IGF) and IGF type I receptor during postnatal growth of the murine mammary gland: Sites of messenger ribonucleic acid expression and potential functions. Endocrinology 1999; 140(1):454–461.PubMedGoogle Scholar
  27. 27.
    Ruan W, Kleinberg DL. Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 1999; 140(11):5075–5081.PubMedGoogle Scholar
  28. 28.
    Hadsell DL, Greenberg NM, Fligger JM et al. Targeted expression of des(1–3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 1996; 137(1):321–330.PubMedGoogle Scholar
  29. 29.
    Hadsell DL, Bonnette SG, Lee AV. Genetic manipulation of the IGF-I axis to regulate mammary gland development and function. J Dairy Sci 2002; 85(2):365–377.PubMedGoogle Scholar
  30. 30.
    Gilmore AP, Valentijn AJ, Wang P et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor., J Biol Chem 2002; 277(31):27643–27650.PubMedGoogle Scholar
  31. 31.
    Marshman E, Streuli CH. Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 2002; 4(6):231–239.PubMedGoogle Scholar
  32. 32.
    Tonner E, Barber MC, Allan GJ et al. Insulin-like growth factor binding protein-5 (IGFBP-5) induces premature cell death in the mammary glands of transgenic mice. Development 2002; 129(19):4547–4557.PubMedGoogle Scholar
  33. 33.
    Toniolo P, Bruning PF, Akhmedkhanov A et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000; 88(5):828–832.PubMedGoogle Scholar
  34. 34.
    Paik S. Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 1992; 22(1):31–38.PubMedGoogle Scholar
  35. 35.
    Ruan W, Newman CB, Kleinberg DL. Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development. Proc Natl Acad Sci USA 1992; 89(22):10872–10876.PubMedGoogle Scholar
  36. 36.
    Ruan W, Catanese V, Wieczorek R et al. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 1995; 136(3):1296–1302.PubMedGoogle Scholar
  37. 37.
    Wu Y, Cui K, Miyoshi K et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003; 63(15):4384–4388.PubMedGoogle Scholar
  38. 38.
    Hankinson SE, Willett WC, Colditz GA et al Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351(9113):1393–1396.PubMedGoogle Scholar
  39. 39.
    Cullen KJ, Yee D, Sly WS et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 1990; 50(1):48–53.PubMedGoogle Scholar
  40. 40.
    Pezzino V, Papa V, Milazzo G et al. Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Ann NY Acad Sci 1996; 784:189–201.PubMedGoogle Scholar
  41. 41.
    Turner BC, Haffty BG, Narayanan L et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57(15):3079–3083.PubMedGoogle Scholar
  42. 42.
    Rocha RL, Hilsenbeck SG, Jackson JG et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival. Clin Cancer Res 1997; 3(1):103–109.PubMedGoogle Scholar
  43. 43.
    Lee AV, Jackson JG, Gooch JL et al. Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999; 13(5):787–796.PubMedGoogle Scholar
  44. 44.
    Hoang CD, Zhang X, Scott PD et al. Selective activation of insulin receptor substrate-1 and −2 in pleural mesothelioma cells: Association with distinct malignant phenotypes. Cancer Res 2004; 64(20):7479–7485.PubMedGoogle Scholar
  45. 45.
    Zhang X, Kamaraju S, Hakuno F et al. Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat 2004; 83(2):161–170.PubMedGoogle Scholar
  46. 46.
    Nagle JA, Ma Z, Byrne MA et al. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 2004; 24(22):9726–9735.PubMedGoogle Scholar
  47. 47.
    Perks CM, Bowen S, Gill ZP et al. Differential IGF-independent effects of insulin-like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells. J Cell Biochem 1999; 75(4):652–664.PubMedGoogle Scholar
  48. 48.
    Oh Y, Muller HL, Lamson, G et al. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 1993; 268(20):14964–14971.PubMedGoogle Scholar
  49. 49.
    Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100(7):3983–3988.PubMedGoogle Scholar
  50. 50.
    Baselga J, Norton L. Focus on breast cancer. Cancer Cell 2002; 1(4):319–322.PubMedGoogle Scholar
  51. 51.
    Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998; 351(9114):1451–1467.Google Scholar
  52. 52.
    Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 1995; 73(3):311–331.PubMedGoogle Scholar
  53. 53.
    Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death—proliferative and anti-apoptotic effects. Breast Cancer Res Treat 1999; 56(1):1–10.PubMedGoogle Scholar
  54. 54.
    Xie SP, Pirianov G, Colston KW. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur J Cancer 1999; 35(12):1717–1723.PubMedGoogle Scholar
  55. 55.
    Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997; 17(3):1595–1606.PubMedGoogle Scholar
  56. 56.
    Kothari S, Cizeau J, McMillan-Ward E et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 2003; 22(30):4734–4744.PubMedGoogle Scholar
  57. 57.
    Peruzzi F, Prisco M, Dews M et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999; 19(10):7203–7215.PubMedGoogle Scholar
  58. 58.
    Zha J, Harada H, Yang E et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87(4):619–628.PubMedGoogle Scholar
  59. 59.
    Singleton JR, Dixit VM, Feldman EL. Type I insulin-like growth factor receptor activation regulates apoptotic proteins. J Biol Chem 1996; 271(50):31791–31794.PubMedGoogle Scholar
  60. 60.
    Dunn SE, Hardman RA, Kari FW et al. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997; 57(13):2687–2693.PubMedGoogle Scholar
  61. 61.
    Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004; 108(3):334–341.PubMedGoogle Scholar
  62. 62.
    Mamay CL, Mingo-Sion AM, Wolf DM et al. An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer. Oncogene 2003; 22(4):602–614.PubMedGoogle Scholar
  63. 63.
    Heron-Milhavet L, Karas M, Goldsmith CM et al. Insulin-like growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair. J Biol Chem 2001; 276(21):18185–18192.PubMedGoogle Scholar
  64. 64.
    Heron-Milhavet L, LeRoith D. Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 2002; 277(18):15600–15606.PubMedGoogle Scholar
  65. 65.
    Shahrabani-Gargir L, Pandita TK, Werner H. Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology 2004; 145(12):5679–5687.PubMedGoogle Scholar
  66. 66.
    Kuhn C, Hurwitz SA, Kumar MG et al. Activation of the insulin-like growth factor-1 receptor promotes the survival of human keratinocytes following ultraviolet B irradiation. Int J Cancer 1999; 80(3):431–438.PubMedGoogle Scholar
  67. 67.
    Decraene D, Agostinis P, Bouillon R et al. Insulin-like growth factor-1-mediated AKT activation postpones the onset of ultraviolet B-induced apoptosis, providing more time for cyclobutane thymine dimer removal in primary human kerationocytes. J Biol Chem 2002; 277(36):32587–32595.PubMedGoogle Scholar
  68. 68.
    Trojanek J, Ho T, Del Valle L et al. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol 2003; 23(21):7510–7524.PubMedGoogle Scholar
  69. 69.
    Jayanth VR, Belfi CA, Swick AR et al. Insulin and insulin-like growth factor-1 (IGF-1) inhibit repair of potentially lethal radiation damage and chromosome aberrations and alter DNA repair kinetics in plateau-phase A549 cells. Radiat Res 1995; 143(2):165–174.PubMedGoogle Scholar
  70. 70.
    Holdaway IM, Mason BH, Lethaby AE et al. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg 2003; 73(11):905–908.PubMedGoogle Scholar
  71. 71.
    Kajdaniuk D, Marek B. Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma insulin-like growth factor-I and chosen hormones in breast cancer premenopausal patients. J Clin Pharm Ther 2000; 25(1):67–72.PubMedGoogle Scholar
  72. 72.
    Formelli F. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial. J Cell Biochem Suppl 2000; 34:73–79.PubMedGoogle Scholar
  73. 73.
    Yang LM, Tin UC, Wu K et al. Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia 1999; 4(4):377–388.PubMedGoogle Scholar
  74. 74.
    Chrzanowski K, Bielawska A, Palka J. Proline analogue of melphalan as a prodrug susceptible to the action of prolidase in breast cancer MDA-MB 231 cells. Farmaco 2003; 58(11):1113–1119.PubMedGoogle Scholar
  75. 75.
    Gronbaek H, Tanos V, Meirow D et al. Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. Anticancer Res 2003; 23(3C):2815–2820.PubMedGoogle Scholar
  76. 76.
    Ferrari L, Bajetta E, Martinetti A et al. Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole. Int J Oncol 2003; 22(5):1081–1089.PubMedGoogle Scholar
  77. 77.
    Torrisi R, Baglietto L, Johansson H et al. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br J Cancer 2001; 85(12):1838–1841.PubMedGoogle Scholar
  78. 78.
    Nielsen TO, Andrews HN, Cheang M et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: Potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004; 64(1):286–291.PubMedGoogle Scholar
  79. 79.
    Jerome L, Shiry L, Leyland-Jones B. Anti-insulin-like growth factor strategies in breast cancer. Semin Oncol 2004; 31(1 Suppl 3):54–63.PubMedGoogle Scholar
  80. 80.
    Byron SA, Yee D. Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. Semin Oncol 2003; 30(5 Suppl 16):125–132.PubMedGoogle Scholar
  81. 81.
    Szepeshazi K, Schally AV, Armatis P et al. Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 2001; 142(10):4371–4378.PubMedGoogle Scholar
  82. 82.
    Kahan Z, Varga JL, Schally AV et al. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat 2000; 60(1):71–79.PubMedGoogle Scholar
  83. 83.
    Ingle JN, Suman VJ, Kardinal CG et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999; 85(6):1284–1292.PubMedGoogle Scholar
  84. 84.
    Friend KE. Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm IGF Res 2001; 11(Suppl A):S121–123.Google Scholar
  85. 85.
    Van den Berg CL, Cox GN, Stroh CA et al. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer 1997; 33(7):1108–1113.PubMedGoogle Scholar
  86. 86.
    Yee D, Jackson JG, Kozelsky TW et al. Insulin-like growth factor binding protein-1 (IGFBP-1) expression inhibits IGF-I action in MCF-7 breast cancer cells. Cell Growth and Differentiation 1994; 5:73–77.PubMedGoogle Scholar
  87. 87.
    Zi X, Zhang J, Agarwal R et al. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 2000; 60(20):5617–5620.PubMedGoogle Scholar
  88. 88.
    D’Ambrosio C, Ferber A, Resnicoff M et al. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 1996; 56(17):4013–4020.PubMedGoogle Scholar
  89. 89.
    Samani AA, Chevet E, Fallavollita L et al. Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res 2004; 64(10):3380–3385.PubMedGoogle Scholar
  90. 90.
    Goya M, Miyamoto S, Nagai K et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004; 64(17):6252–6258.PubMedGoogle Scholar
  91. 91.
    Arteage CL, Kitten LJ, Coronado EB et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989; 84(5):1418–1423.Google Scholar
  92. 92.
    Li SL, Liang SJ, Guo N et al. Single-chain antibodies against human insulin-like growth factor I receptor: Expression, purification, and effect on tumor growth. Cancer Immunol Immunother 2000; 49(4–5):243–252.PubMedGoogle Scholar
  93. 93.
    Sachdev D, Li SL, Hartell JS et al. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003; 63(3):627–635.PubMedGoogle Scholar
  94. 94.
    Ye JJ, Liang SJ, Guo N et al. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res 2003; 35(11–12):836–842.PubMedGoogle Scholar
  95. 95.
    Maloney EK, McLaughlin JL, Dagdigian NE et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63(16):5073–5083.PubMedGoogle Scholar
  96. 96.
    Burtrum D, Zhu Z, Lu D et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63(24):8912–8921.PubMedGoogle Scholar
  97. 97.
    Blum G, Gazit A, Levitzki A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 2003; 278(42):40442–40454.PubMedGoogle Scholar
  98. 98.
    Parrizas M, Gazit A, Levitzki A et al. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 1997; 138(4):1427–1433.PubMedGoogle Scholar
  99. 99.
    Mitsiades CS, Mitsiades NS, McMullan CJ et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5(3):221–230.PubMedGoogle Scholar
  100. 100.
    Garcia-Echeverria C, Pearson MA, Marti A et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5(3):231–239.PubMedGoogle Scholar
  101. 101.
    Salatino M, Schillaci R, Proietti CJ et al. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 2004; 23(30):5161–5174.PubMedGoogle Scholar
  102. 102.
    Beech DJ, Parekh N, Pang Y. Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncol Rep 2001; 8(2):325–329.PubMedGoogle Scholar
  103. 103.
    Benini S, Manara MC, Baldini N et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing’s sarcoma cells. Clin Cancer Res 2001; 7(6):1790–1797.PubMedGoogle Scholar
  104. 104.
    Camirand A, Pollak M. Cotargeting IGF-1 R and c-kit: Synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 2004; 90(9):1825–1829.PubMedGoogle Scholar
  105. 105.
    Baserga R. Targeting the IGF-1 receptor; From rags to riches. Eur J Cancer 2004; 40(14):2013–2015.PubMedGoogle Scholar
  106. 106.
    Albain KS, Green SJ, Ravdin PM et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814). Proc ASCO 2002, (Abs#:143).Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2007

Authors and Affiliations

  1. 1.Department of Pharmacology and MedicineUniversity of Minnesota Cancer Center, MMC 806MinneapolisUSA

Personalised recommendations